Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.

Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 2006;26(6):571-8. DOI: 10.1097/01.jcp.0000246215.49271.b8. PubMed PMID: 17110813.

Treatment of clozapine-associated weight gain: a systematic review.

Whitney Z, Procyshyn RM, Fredrikson DH, Barr AM. Treatment of clozapine-associated weight gain: a systematic review. Eur J Clin Pharmacol. 2015;71(4):389-401. DOI: 10.1007/s00228-015-1807-1. PubMed PMID: 25627831.

A review of clozapine safety.

Fitzsimons J, Berk M, Lambert T, Bourin M, Dodd S. A review of clozapine safety. Expert Opin Drug Saf. 2005;4(4):731-44. DOI: 10.1517/14740338.4.4.731. PubMed PMID: 16011451.

A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls.

Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45(6):458-65. DOI: 10.3109/00048674.2011.572852. PubMed PMID: 21524186.

Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives.

Lang UE, Willbring M, von Golitschek R, Schmeisser A, Matschke K, Malte Tugtekin S. Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. J Psychopharmacol. 2008;22(5):576-80. DOI: 10.1177/0269881107082136. PubMed PMID: 18308817.

Rapid Rechallenge with Clozapine Following Pronounced Myocarditis in a Treatment-Resistant Schizophrenia Patient.

Ittasakul P, Archer A, Kezman J, Atsariyasing W, Goldman MB. Rapid Rechallenge with Clozapine Following Pronounced Myocarditis in a Treatment-Resistant Schizophrenia Patient. Clin Schizophrenia Relat Psychoses. 2016;10(2):120-2. DOI: 10.3371/1935-1232-10.2.120. PubMed PMID: 27440213.

Successful clozapine retrial after suspected myocarditis.

Rosenfeld AJ, Gibbs T, Ivie R, Clarke L, Merrill DB. Successful clozapine retrial after suspected myocarditis. AJP. 2010;167(3):350-1. DOI: 10.1176/appi.ajp.2009.09081118. PubMed PMID: 20194490.

An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother. 2011;12(13):2009-24. DOI: 10.1517/14656566.2011.587122. PubMed PMID: 21635198; PubMed Central PMCID: PMC3152685.

Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group.

Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet. 1999;353(9169):2041-2. PubMed PMID: 10376627.

Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.

Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999;340(10):757-63. DOI: 10.1056/NEJM199903113401003. PubMed PMID: 10072410.